// Biotech and Pharma Therapeutics
4 Notable Health Tech Funding Announcements in December
December 31, 2025 / Health Tech Funding / AI in Healthcare / Digital Health Solutions / Clinical Trial Access / Employer Health Plans
December saw major health tech investments in AI-driven care platforms, employer-based health plans, and clinical trial access tools, signaling growing demand for digital solutions to improve healthcare delivery, equity, and operational efficiency.
10 Big Moments in Medtech
December 30, 2025 / Medtech Innovation / Medical Devices / Digital Health Trends / Healthcare Technology / Regulatory Changes
Key milestones in medtech during 2025—from regulatory shifts to breakthrough innovations—are poised to reshape patient care, digital health, and medical device strategy, signaling long-term impacts across clinical practice and industry development.
Physician Assistant Trends 2026: AI Adoption, Title Changes, and Workforce Growth
December 30, 2025 / Physician Assistants / AI in Healthcare / Clinical Workforce Trends / Healthcare Education Gap / Title Change Debate
Physician Assistants are rapidly adopting AI despite limited training, pushing for a professional title change, and facing an education-practice gap—highlighting urgent needs in clinical governance, role clarity, and workforce support as the profession expands through 2034.
Cost Control Takes Center Stage as Hospitals Prepare to Navigate 2026
December 30, 2025 / Hospital Cost Control / Healthcare Staffing / Revenue Cycle Management / Financial Pressures 2026 / Health System Strategy
In response to 2025’s financial strain from labor, supply, and revenue cycle pressures, hospitals are prioritizing cost control strategies like staffing optimization and outsourcing to stabilize operations heading into 2026.
Key Ways To Manage Liability Risk For High-Tech Implantable Devices
December 28, 2025 / Medical Device Liability / Implantable Device Insurance / Risk Management Strategy / Product Lifecycle Coverage / Regulatory Compliance
Managing liability for high-tech implantable devices requires lifecycle-aligned insurance, early risk assessment, team training, and global-ready coverage to mitigate legal exposure, enhance patient safety, and support regulatory compliance throughout product development and commercialization.
// 4th Industrial Revolution
Cleveland Clinic offers tips on ambient AI deployment, from evaluation to scale
December 31, 2025 / Ambient AI Healthcare / Clinical Documentation Tools / Physician Burnout Solutions / Health IT Strategy / AI in Ambulatory Care
Cleveland Clinic successfully scaled ambient AI across 80+ specialties by focusing on clinician trust, workflow integration, and leadership alignment—reducing documentation burden, improving care quality, and offering a replicable model for enterprise-wide adoption.
How to Navigate the Triad of Audits in Medical Device Compliance
December 31, 2025 / Medical Device Audits / MDR Compliance / MDSAP Strategy / FDA Inspection Prep / QMSR Transition
Navigating MDR, MDSAP, and FDA audits requires a strategic, risk-based approach. Tailored preparation, including mock audits and quality system alignment, is essential for global compliance and readiness for the QMSR transition in 2026.
DEA, HHS extend telemedicine flexibilities for remote prescribing of controlled substances
December 31, 2025 / Telemedicine Extension / Controlled Substance Prescribing / DEA Regulations / Remote Opioid Treatment / Telehealth Policy 2026
DEA and HHS extended telemedicine flexibilities for prescribing Schedule II-V controlled substances through 2026, preserving remote access for patients while averting the “telemedicine cliff” and emphasizing safe, compliant care continuity via virtual prescribing.
Building Member Trust with GenAI in Prior Authorization
December 31, 2025 / Prior Authorization AI / Member Trust Healthcare / Generative AI Governance / Digital Health Equity / Payer Technology Strategy
Generative AI can streamline prior authorization and rebuild member trust when guided by responsible governance, transparency, and member-first design—bridging digital gaps, reducing denials, and improving healthcare access and decision-making for patients navigating complex payer systems.
AI Decides Who Gets Care: Algorithmic Bias in Post-Acute Care Decisions
December 31, 2025 / Algorithmic Bias Healthcare / Post-Acute AI Tools / AI Coverage Decisions / Health Equity Technology / CMS AI Regulations
AI-driven post-acute care tools risk reinforcing healthcare disparities through algorithmic bias and lack of context. Emerging regulations aim to ensure transparency, clinician oversight, and equity in AI-assisted coverage decisions, especially for vulnerable and underserved populations.
// Business & Markets
AI benefits platform Healthee partners with Health Benefits Alliance
December 31, 2025 / AI Health Navigation / Employee Benefits Platform / Telehealth Integration / Mental Health Access / Healthcare Cost Transparency
Healthee and The Health Benefits Alliance have partnered to integrate AI-driven benefits navigation, telehealth access, and mental health services into a unified platform, aiming to enhance care accessibility, cost transparency, and employee engagement across benefit plans.
Lupin signs exclusive GLP-1 licensing deal with Gan & Lee
December 31, 2025 / GLP-1 Therapy / Type 2 Diabetes Treatment / Obesity Management Drug / Bofanglutide Injection / Lupin Gan & Lee
Lupin has secured exclusive rights to bofanglutide, a novel fortnightly GLP-1 receptor agonist from Gan & Lee, enhancing its diabetes and obesity pipeline with a promising treatment offering comparable efficacy and improved dosing convenience.
Cipla launches India’s only inhaled insulin, Afrezza
December 31, 2025 / Inhaled Insulin India / Afrezza Launch Cipla / Diabetes Needle-Free Treatment / Rapid Acting Insulin / CDSCO Diabetes Approval
Cipla has launched Afrezza, India’s first inhaled insulin, offering a needle-free, rapid-acting alternative for diabetes management. This innovative therapy enhances convenience, mimics natural insulin response, and expands treatment options for millions of Indian adults with diabetes.
NIH begins review of thousands of delayed research proposals, funding 135 on first day
December 30, 2025 / NIH Grant Review / DEI Research Funding / Health Disparities Studies / Science Workforce Diversity / Research Proposal Delays
NIH has begun reviewing delayed research proposals previously paused due to anti-DEI policies, funding 135 projects on day one. The move revives critical studies focused on health disparities and workforce diversity, following a legal settlement mandating merit-based evaluations.
CMS announces Rural Health Transformation Program awards
December 30, 2025 / Rural Health Funding / CMS Transformation Program / Hospital Modernization Grants / Healthcare IT Innovation / Rural Hospital Closures
CMS awarded all 50 states funding under the $50 billion Rural Health Transformation Program to modernize rural healthcare through IT innovation, improve care coordination, and prevent hospital closures amid ongoing challenges in underserved communities.
// Legal & Regulatory
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
December 29, 2025 / Hyperphosphatemia Treatment / CKD Dialysis Patients / Oxylanthanum Carbonate NDA / FDA Resubmission Update / Unicycive Therapeutics Drug
Unicycive Therapeutics has resubmitted its NDA for oxylanthanum carbonate, an oral phosphate binder for dialysis patients with hyperphosphatemia, after resolving FDA manufacturing compliance issues. The company anticipates regulatory review completion within six months.
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
December 29, 2025 / Essential Tremor Treatment / FDA Breakthrough Designation / Ulixacaltamide Clinical Trials / CNS Disorder Therapy / Praxis Precision Medicines
Praxis Precision Medicines received FDA Breakthrough Therapy Designation for ulixacaltamide, a selective T-type calcium channel blocker, based on strong Phase 3 data for essential tremor. NDA submission is expected in early 2026.
Combining AI and human review to enhance claims accuracy
December 29, 2025 / AI Medical Coding / Clinical Denial Reduction / Claims Accuracy Solutions / Physician Review Integration / Healthcare Documentation AI
Accuity combines AI-driven medical record analysis with physician-led review to enhance claims accuracy, reduce clinical denials, and improve documentation and coding quality for healthcare providers.
FDA Finds Insufficient Data to Determine Safety of PFAS in Cosmetic Products
December 29, 2025 / PFAS Cosmetics Safety / FDA MoCRA Report / Toxicology Data Gaps / Cosmetic Ingredient Regulation / Consumer Product Oversight
The FDA’s evaluation of PFAS in cosmetics found insufficient toxicological data to determine safety, highlighting significant data gaps and uncertainty. Ongoing research and interagency collaboration aim to strengthen oversight and reduce PFAS exposure across consumer products.
Global drugmakers lose legal battles in Russian pharma market
December 30, 2025 / Patent Disputes Russia / Generic Drug Launch / Pharma IP Enforcement / Antitrust Rulings Overturned / Global Pharma Legal Challenges
Russian courts are overturning antitrust rulings against local drugmakers who launched generics of patented anticancer drugs early, undermining global pharma firms like Pfizer and Novartis and raising concerns over IP enforcement in Russia’s pharmaceutical market.
// Research & Development
Researchers find ADHD strengths linked to better mental health
December 31, 2025 / ADHD Mental Health / Strengths-Based Approach / Creativity Hyperfocus Benefits / ADHD Quality of Life / Positive ADHD Traits
A new study finds that adults with ADHD who recognize and apply personal strengths—like creativity and hyperfocus—report improved mental health, reduced stress, and enhanced quality of life, highlighting a strengths-based approach to ADHD support.
New milestone in breast cancer prevention claimed by Greenwich
December 31, 2025 / Breast Cancer Recurrence / HER2+ Immunotherapy / GLSI-100 Clinical Trial / Cancer Prevention Breakthrough / Greenwich LifeSciences Study
Greenwich LifeSciences’ Phase III trial reports an 80% reduction in breast cancer recurrence using GLSI-100 immunotherapy in high-risk HER2+ patients, reinforcing earlier Phase IIb results and marking a major advance in long-term prevention post-standard treatment.
New computational method reconstructs how cells decide their fate
December 30, 2025 / Cell Fate Mapping / ddHodge Computational Method / Single-Cell RNA-Seq / High-Dimensional Biology / Cell State Dynamics
Kyushu University researchers developed ddHodge, a novel computational method that preserves geometric data to accurately map how cells transition between states, offering new insights into cell fate decisions in development, regeneration, and disease.
What cannabis really does for chronic pain
December 30, 2025 / Cannabis Chronic Pain / THC Neuropathic Pain / CBD Pain Evidence / Medical Marijuana Research / Chronic Pain Treatment
Clinical trial reviews show high-THC cannabis may provide modest, short-term relief for chronic, especially neuropathic, pain, but with increased side effects. CBD-only products showed no clear benefit, underscoring the need for robust long-term pain studies.
Biomimetic brain modeling mirrors animal learning and neural dynamics
December 30, 2025 / Biomimetic Brain Model / Neural Dynamics Simulation / AI Neuroscience Platform / Computational Neuroscience Research / Neurotherapeutic Discovery Tools
Researchers developed a biologically realistic brain model that mimics animal learning and neural dynamics without training on real data, revealing new insights into cognition, disease mechanisms, and accelerating neurotherapeutic discovery through a biomimetic AI platform.
// Politics
Shadow AI and the Governance Gap: Leading Healthcare Through the GenAI Revolution
December 31, 2025 / Generative AI Healthcare / Shadow AI Risk / Clinical Decision Support / AI Governance Oversight / Healthcare Innovation Strategy
Generative AI offers transformative potential in healthcare, but risks like shadow AI and inadequate governance threaten safety, trust, and equity. Strong oversight, clinician training, and evidence-based implementation are essential to harness AI’s value while protecting patient care.
The MAHA Paradox: How Medical Device Tariffs Undermine “Make America Healthy Again
December 31, 2025 / Medical Device Tariffs / Health Tech Access / Affordable Care Tools / Public Health Policy / Make America Healthy
Proposed medical device tariffs undercut the “Make America Healthy Again” agenda by raising costs, limiting access to essential health tech, and threatening innovation. Affordable, imported devices are vital for public health, especially for underserved and remote populations.
Trump administration agrees to reconsider frozen and denied NIH grant submissions related to DEI
December 29, 2025 / NIH Grant Reinstatement / DEI Research Funding / Scientific Merit Review / Federal Research Policy / Trump Administration Lawsuit
The Trump administration agreed to allow NIH to re-review frozen or denied grant applications tied to DEI, reversing prior political interference and restoring scientific merit as the standard for funding decisions amid ongoing legal challenges.
TrumpRx signs agreement with nine new pharma manufacturers
December 29, 2025 / TrumpRx Drug Discounts / Pharmaceutical Price Reductions / U.S. Drug Manufacturing / Medication Access Program / Strategic API Reserve
TrumpRx expanded its discounted drug program by partnering with nine major pharmaceutical companies, offering lower prices on key medications and boosting U.S. manufacturing, while aiming to strengthen domestic supply chains and reduce dependence on foreign drug production.
Chinese siRNA biotech expects $188M IPO; InflaRx seeks Gohibic revival in rare skin condition
December 29, 2025 / siRNA Biotech IPO / Gohibic Skin Treatment / Rare Disease Therapeutics / Biopharma Pipeline Updates / Global Drug Development
A Chinese siRNA biotech plans a $188M IPO, while InflaRx aims to repurpose Gohibic for a rare skin condition. Other updates include pipeline and funding news from ASK Pharm, Unicycive, Harbour BioMed, Gilead, and more.